Alexander G Semenov
Overview
Explore the profile of Alexander G Semenov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li L, Semenov A, Feygina E, Yang C, Wang N, Chen C, et al.
Clin Chem Lab Med
. 2022 Dec;
61(3):485-493.
PMID: 36457141
Objectives: The N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) is a widely used heart failure (HF) biomarker. Commercial NT-proBNP immunoassays detect only a subfraction of endogenous NT-proBNP, as the antibodies...
2.
3.
Feygina E, Artemieva M, Postnikov A, Tamm N, Bloshchitsyna M, Medvedeva N, et al.
Clin Chem
. 2019 Jul;
65(10):1239-1247.
PMID: 31307994
Background: Entresto™ is a new heart failure (HF) therapy that includes the neprilysin (NEP) inhibitor sacubitril. One of the NEP substrates is B-type natriuretic peptide (BNP); its augmentation by NEP...
4.
5.
Semenov A, Feygina E
Adv Clin Chem
. 2018 Apr;
85:1-30.
PMID: 29655458
Brain natriuretic peptide (BNP) and the N-terminal fragment of the BNP precursor (NT-proBNP) are widely used as heart failure (HF) biomarkers. Since the discovery of BNP in 1988, much effort...
6.
Semenov A, Tamm N, Apple F, Schulz K, Love S, Ler R, et al.
Clin Biochem
. 2016 Nov;
50(4-5):181-185.
PMID: 27823960
Background: Circulating B-type natriuretic peptide (BNP) is widely accepted as a diagnostic and risk assessment biomarker of cardiac function. Studies suggest that there are significant differences in measured concentrations among...
7.
Semenov A, Katrukha A
EJIFCC
. 2016 Sep;
27(3):189-207.
PMID: 27683533
Natriuretic peptides (NPs) were first described as cardiac biomarkers more than two decades ago. Since that time, numerous studies have confirmed NPs' diagnostic and prognostic utilities as biomarkers of myocardial...
8.
Semenov A, Katrukha A
Clin Chem
. 2016 Feb;
62(4):617-22.
PMID: 26864319
Background: Protease neprilysin is known to be responsible for the degradation of natriuretic peptides. A recent heart failure (HF) drug, LCZ696 (Entresto(TM)), that combines a neprilysin inhibitor and an angiotensin...
9.
Semenov A, Seferian K, Tamm N, Artemeva M, Postnikov A, Bereznikova A, et al.
Clin Chem
. 2011 Apr;
57(6):883-90.
PMID: 21474642
Background: The appearance of B-type natriuretic peptide (BNP) in the blood is ultimately caused by proteolytic processing of its precursor, proBNP. The mechanisms leading to the high plasma concentration of...
10.
Semenov A, Seferian K
Clin Chim Acta
. 2011 Mar;
412(11-12):850-60.
PMID: 21396929
B-type Natriuretic Peptide (BNP) is a circulating hormone primarily produced by the myocardium in response to volume overload and increased filling pressure. BNP acts to increase natriuresis and to decrease...